QQ客服 官方微博 反馈留言

	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors
	Cao, Junning; Zhang, Jian; Peng, Wei; Chen, Zhiyu; Fan, Songhua; Su, Weiguo; Li, Ke; Li, Jin
刊名	CANCER CHEMOTHERAPY AND PHARMACOLOGY
	2016
卷号	78期号:2
关键词	Fruquintinib Phase I study VEGFR Advanced solid tumors Safety and pharmacokinetics
ISSN号	0344-5704
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4285272
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Cao, Junning,Zhang, Jian,Peng, Wei,et al. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY,2016,78(2).
APA	Cao, Junning.,Zhang, Jian.,Peng, Wei.,Chen, Zhiyu.,Fan, Songhua.,...&Li, Jin.(2016).A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors.CANCER CHEMOTHERAPY AND PHARMACOLOGY,78(2).
MLA	Cao, Junning,et al."A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors".CANCER CHEMOTHERAPY AND PHARMACOLOGY 78.2(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。